Cellivery Therapeutics, Inc.

A268600

KR7268600004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 04:30:00 23/03/2023 am IST			5-day change	1st Jan Change
6,680 ^KRW	-29.91%		-.--%	-.--%

2023	Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	CI
2021	Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	CI

Cellivery Therapeutics, Inc.(KOSDAQ:A268600) added to S&P Global BMI Index

March 18, 2019 at 09:30 am IST

Latest news about Cellivery Therapeutics, Inc.

Cellivery Therapeutics, Inc.(KOSDAQ:A268600) dropped from S&P Global BMI Index	05/23/05	CI
Cellivery Therapeutics, Inc. acquired Ajin Clean Co., Ltd. from SVAJ Holdings for KRW 14.2 billion.	17/21/17	CI
Cellivery Therapeutics, Inc. agree to acquire Ajin Clean Co., Ltd. for KRW 14.9 billion.	16/21/16	CI
Cellivery Therapeutics, Inc. announced that it has received KRW 38.9997004 billion in funding	15/21/15	CI
Cellivery Therapeutics to Raise Nearly $17 Million Through Stock Sale	01/21/01	MT
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 38.9997004 billion in funding	30/21/30	CI
Cellivery Therapeutics to Raise $13 Million from Stock Offering	24/21/24	MT
Cellivery Therapeutics, Inc. announced that it has received KRW 43.9988081 billion in funding from a group of investors	19/20/19	CI
Cellivery Therapeutics, Inc. announced that it expects to receive KRW 43.9988081 billion in funding from a group of investors	06/20/06	CI
Cellivery Therapeutics, Inc.(KOSDAQ:A268600) added to S&P Global BMI Index	18/19/18	CI
Cellivery Therapeutics, Inc has completed an IPO in the amount of KRW 28.5 billion.	08/18/08	CI
Cellivery Therapeutics, Inc has filed an IPO.	11/18/11	CI

Chart Cellivery Therapeutics, Inc.

Duration

Period

More charts

Cellivery Therapeutics, Inc. is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinsonâs disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Sector

Biotechnology & Medical Research

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CELLIVERY THERAPEUTICS, INC.	-.--%	178M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B